SF3B1 and myeloid neoplasm: According to the 2022 International Consensus Classification of myeloid neoplasms and acute leukemia (20), a diagnosis of SF3B1-mutant myelodysplastic syndrome can be made when an SF3B1 mutation is present and RSs comprise ≥5% of erythroid precursors.